Lynovex

Lynovex® (NM001) is a first-in-class orphan drug candidate for cystic fibrosis.

NovaBiotics recognises more treatments, and better treatments, are desperately needed to address these symptoms.

Our solution is Lynovex® (NM001), which is being developed to improve the quality & length of life of all CF patients – not just those with particular CFTR genotypes.

See the effect of Lynovex on cystic fibrosis sputum

What Is Lynovex?
The Story So Far
Clinical Studies
Lynovex® Latest

Lynovex® Latest

Grant Support for Lynovex

Data On The Mucolytic Mechanism Of Action Of Lynovex Will Be Presented At Nacfc 2018.

Care Cf 1 Lynovex Clinical Trial Data Selected For Presentation At Nacfc 2018.

Lynovex Oral meets study objectives for CARE CF 1 Clinical Trial

Cysteamine, An Endogenous Aminothiol, And Cystamine, The Disulfide Product Of Oxidation, Increase Pseudomonas Aeruginosa Sensitivity To Reactive Oxygen And Nitrogen Species And Potentiate Therapeutic Antibiotics Against Bacterial Infection.